ライフサイエンスコーパス: artificial tear

1 dry eye who would benefit from a lipid-based artificial tear.

2 acy and tolerability versus cyclosporine and artificial tears.

3 eal thickness obtained after instillation of artificial tears.

4 eal thickness obtained after instillation of artificial tears.

5 % diclofenac sodium; and group IV, control + artificial tears.

6 D below the mean value for eyes administered artificial tears.

7 cal NSAIDs, while the control group received artificial tears.

8 lity in older adult patients and those using artificial tears.

9 eparated by 28(+/- 3) days of treatment with artificial tears.

10 d with a nationwide outbreak of contaminated artificial tears.

11 ditional therapies such as preservative free artificial tears.

12 ndomised 1:1 to receive laughter exercise or artificial tears (0.1% sodium hyaluronic acid eyedrop, c

13 Compared to artificial tears, 2% RBM improved TBUT and subjective sy

14 The results demonstrated that compared with artificial tears, 2% RBM significantly increased the TBU

15 Following a 14-day run-in period with an artificial tear administered 2 times per day, eligible p

16 Immediately after instillation of artificial tears, all measured variables increased signi

17 It is presently treated with artificial tear and anti-inflammatory eye drops that are

18 In the artificial tear and loteprednol groups, although no sign

19 patients with presbyopia who were started on artificial tears and had no history of topical pilocarpi

20 mental modifications, dietary modifications, artificial tears and lubricants, punctal occlusion, inte

21 During a period of dry eye, artificial tears and punctal plugs are helpful in preven

22 ces in therapy include improved nonpreserved artificial tears and therapies targeted at decreasing oc

23 gical ointment, 0.1% cyclosporine eye drops, artificial tears, and 0.5% loteprednol for keratoplasty

24 DED by a clinician, (2) the prescription of artificial tears, and/or (3) symptoms of dry eyes for at

25 Patients were using artificial tears as needed.

26 allergic reaction followed by application of artificial tears (ATs), 5 minutes of cold compress (CC),

27 Only patients who did not use artificial tears before the surgery and who had not been

28 Artificial tears combined with CC reduced hyperemia more

29 hours, or a single drop of preservative-free artificial tears (control group).

30 We prescribed artificial tear drop and night-time liquid tear gel.

31 Remarkably, acquisition of artificial tears, eye care wipes, and several ophthalmol

32 roximately 0.15 mM glucose concentrations in artificial tear fluid solution.

33 They then used artificial tears for 2 weeks prior to low-humidity expos

34 lol 0.5% eye drops, or Group 2, who received artificial tears for 6 months.

35 treatment groups: group I, 0.5% cidofovir + artificial tears; group II, 0.5% cidofovir + 0.5% ketoro

36 in the adverse events between the 2% RBM and artificial tears groups were nonsignificant (SMD = 1.23,

37 ed that four of the six animals administered artificial tears had damage involving 100% of the neural

38 C-25 and artificial tears had no effect.

39 ctive techniques showed a positive effect of artificial tears in DED treatment.

40 Artificial tear instillation alone or CC combined with A

41 red to both eyes twice daily for 7 days, and artificial tears, ketorolac, and diclofenac four times d

42 riamcinolone acetonide (TA), and lipid-based artificial tears (LBAT)-were tested in cadaveric porcine

43 with DED were randomized to receive topical artificial tears, loteprednol etabonate 0.5%, or lotepre

44 Twice daily applications of either artificial tears (n = 6), 0.5% betaxolol (n = 5), or 0.5

45 therapies such as preserved and nonpreserved artificial tears, nutritional supplements, topical cyclo

46 nts (97%) had used nonprescription eye drops/artificial tears/ointments.

47 ise in measuring the dynamic distribution of artificial tears on the ocular surface.

48 r corneal surgery and 3 days later, received artificial tears or CsA eye drops for 6 weeks.

49 The artificial tears or lubricants are the therapy most used

50 Eight trials compared interventions with artificial tears or saline (n = 4) or with steroids (n =

51 was lower than that in animals administered artificial tears (P = 0.003).

52 ng inadequate sleep (p-value < 0.001), using artificial tears (p-value < 0.001), and number of hours

53 he peptide in one of four delivery vehicles: artificial tears, PBS, methylcellulose, and aquaphor cre

54 treatment); the fellow eye was randomized to artificial tears (placebo).

55 oing SLT were randomized to receive placebo (artificial tears), prednisolone acetate 1%, or ketorolac

56 ender, preoperative and postoperative use of artificial tears, preoperative and postoperative margina

57 overall DED-related symptom scores than did artificial tears (SMD = - 1.61, 95% CI = - 2.61 to - 0.6

58 Commercial artificial tear solution containing hyaluronic acid (HA)

59 each of the first 4 extinction sessions, an artificial tear solution or tetracaine hydrochloride was

60 contact lens care disinfecting solutions or artificial tear solutions containing polyquaternium-1.

61 All received a hyaluronic acid based artificial tear substitute (Hylo-Comod, Ursapharm, Saarb

62 ting of the cornea, by applying and removing artificial tears, temperature changes (35 degrees C-15 d

63 For animals administered artificial tears, the mean IOP of the experimental eyes

64 zed 1:1 to receive a bimatoprost insert plus artificial tears twice daily or a placebo insert plus ti

65 Conversely, older age (P < .001) and artificial tear use (P < .001) were significant predicto

66 Parasol plugs required less frequent artificial tear use at 6 months (P = .024).

67 visual analogue scale [VAS]), and history of artificial tear use within 30 days of study entry.

68 ement in ocular-surface health, reduction in artificial tear use, and improved contact lens comfort i

69 in dry eye symptoms, ocular-surface status, artificial tear use, contact lens comfort, and tear brea

70 aract, pterygium or conjunctivochalasis, and artificial tear use.

71 Overall, artificial tears use was reported by 61 (87%) of 70 case

72 ase-patients had increased odds of receiving artificial tears versus controls (crude matched OR, 5.0;

73 sing the dexamethasone (visit 4) compared to artificial tears (visit 3) (P = .01).

74 No supplemental artificial tears were allowed.

75 t C-25 (10 mug/mL), cyclosporine (0.05%), or artificial tears were topically administered to eyes of

76 n, it was dry eye (42.26%, with major use of artificial tears), with many self-stopping (e.g., gentam